OClawVPS.com
Halozyme, Inc.
Edit

Halozyme, Inc.

http://halozyme.com/
Last activity: 18.03.2026
Active
Categories: BioTechBuildingCommerceDeliveryDevelopmentDrugMedtechProductTechnology
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme's commercially-validated solution has positively impacted more than 400,000 patient lives via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme's proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the company's partners make progress developing and commercializing their products being developed with ENHANZE®.

We are a diverse team, who are committed to bringing therapies and results to patients. It's not enough to be qualified and experienced at what you do, we are looking for people who believe in our mission and match our values.
We are building a company where people can pursue their career goals in a supportive and collaborative team environment. Visit www.halozyme.com/careers for more details.

We are Halozyme.
Followers
369
Website visits
12.3K /mo.
Mentions
46
Location: United States, California, San Diego
Employees: 51-200
Total raised: $150M
Founded date: 1998

Investors 1

Funding Rounds 1

DateSeriesAmountInvestors
05.01.2016-$150M-

Mentions in press and media 46

DateTitleDescription
18.03.2026Breakout Ventures: $114 Million Fund III Launched To Back Frontier Science StartupsBreakout Ventures has announced the close of its $114 million Fund III, marking a new phase of investment focused on science-driven startups at the intersection of biology, chemistry, and artificial intelligence. The San Francisco-based ven...
10.03.2026Breakout Ventures: $114 Million Fund III Launched To Back Science-Driven Startups Using AIBreakout Ventures announced the close of its $114 million Fund III, expanding the venture firm’s efforts to back early-stage companies working at the intersection of science, technology, and artificial intelligence. The San Francisco-based ...
05.02.2026Startups make leadership changes amid growth Loft Dynamics, the pioneer behind the world’s first EASA- and FAA-qualified virtual reality (VR) flight simulators, has appointed Sebastien Borel as chief executive officer, succeeding Founder Fabi Riesen who will serve as chief technology...
27.12.2024FDA approves injectable version of Bristol Myers Squibb's cancer drug OpdivoFDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo By Sneha S K and Sriparna RoyDecember 27, 20245:16 PM UTCUpdated ago Text Small Text Medium Text Large Text Share X Facebook Linkedin Email Link Bottles and a IV b...
25.04.2022Halozyme Buys Antares for $960MIn a deal showcasing Halozyme Therapeutics as an ongoing leader in drug delivery, the San Diego-based biotech announced earlier this month (April 13) it had entered into a definitive agreement to acquire New Jersey-based Antares Pharma for ...
13.04.2022Antares Pharma Stock Soars After $960 Million Halozyme BuyoutShares of Antares Pharma surged 49% Wednesday after the specialty pharmaceutical company agreed to be bought by Halozyme Therapeutics in a cash deal valued at $960 million. Under terms of the deal, Halozyme (ticker: HALO) will pay $5.60 a s...
03.02.2022Halozyme Appoints New Chief Financial OfficerSAN DIEGO, Feb. 2, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Nicole LaBrosse has been promoted to the position of senior vice president, chief financial officer, effective immediately. Ms. LaBrosse...
10.01.2022HALOZYME PROVIDES 2022 FINANCIAL GUIDANCE AND OUTLOOKSAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today introduced 2022 financial guidance and commented on its outlook for the upcoming year. "Halozyme had another strong year of financial performance...
14.12.2021HALOZYME APPOINTS NEW GENERAL COUNSELSAN DIEGO, Dec. 13, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Mark Snyder has been appointed senior vice president, general counsel, chief compliance officer and corporate secretary, effective Janu...
10.12.2021Halozyme Therapeutics, Inc. announces an Equity Buyback for $750 million worth of its shares.Halozyme Therapeutics, Inc. (NasdaqGS:HALO) announces a share repurchase program. Under the program, the company will repurchase up to $750 million worth of its outstanding common stock. The Company plans to fund repurchases from its existi...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In